Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-02-17
2000-10-03
Fonda, Kathleen K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514921, 536 21, A61K 31725
Patent
active
061273473
ABSTRACT:
A method of treating hypovolemic shock and related shock syndromes by the administration of substantially non-anticoagulant heparinoids without the hemorrhaging problems generally associated with heparin; such syndromes include degradation of the microvascular structure, immune and gastrointestinal tract dysfunction, and multiple organ failure.
REFERENCES:
patent: 4847338 (1989-07-01), Linhardt et al.
patent: 4916219 (1990-04-01), Linhardt et al.
patent: 4990502 (1991-02-01), Lormeau et al.
patent: 5034520 (1991-07-01), Lormeau et al.
patent: 5296471 (1994-03-01), Holme et al.
Sharath et al., Immunopharmacology (1985) 9:73-80.
Singh et al., The Journal of Trauma (1993) 34:5:645-652.
Wang et al., American Journal of Physiology (1990) 28:645-650.
Waheed et al., The Journal of Trauma (1992) 32:4:420-426.
Wang et al., Journal of Surgical Research (1993) 54:499-506.
Chaudry et al., The American Journal of Surgery (1993) 165:2A:59S-67S.
Chaudry et al., Immunologic Aspects of Hemorrhage (1992) Chapter 4:35-40.
Cotran et al., Robbins Pathologic Basis of Disease (4th Edition) 114-120. (1989).
Chaudry, et al., A Clinically Relevant Model of Hemorrhagic Shock and Resuscitation in the Rat. Cir. Shock (1989) 27 318.
Chaudry et al., Rat and Mouse Models of Hypovolemic-Traumatic Shock, Pathophysiology of Shock, Sesis, and Organ Failure (1993) pp. 371-383.
Wang, et al. "A novel nonanticoagulant heparin (GM1892) restores cardiovascular and hepatocellular function following trauma-hemorrhage and decreases susceptibility to sepsis" Surgical Forum 45(0): 52-54 (1994).
Fasules, et al. "Neither anticoagulant nor nonanticoagulant heparin affects monocrotaline lung injury" J. Appl. Physiol 62(2): 816-820 (1987).
Singh et al. Presentation and discussion at the Fifty-Second Annual Session of the American Association for the Surgery of Trauma, Sep. 17-19, 1992, Louisville, KY, as described in J. Trauma May 1993, 34(5), 645-652.
Rana et al. J. Trauma 1992, 32(4), 420-426. Month Not Available.
"Dorland's Pocket Medical Dictionary" W.B. Saunders Co., 1989, pp. 539-540. Month Not Available.
Hobson II et al. Microcirc. Endoth. Lymphatics 1989, 5, 259-276. Month Not Available.
Deitch Discussion of the Singh et al. presentation (L) at the Fifty-Second Annual Session of the American Association for the Surgery of Trauma, Sep. 17-19, 1992, Louisville, KY, as described in J. Trauma May 1993, 34(5), 645-652.
Chaudry et al. A Clinically Relevant Model of Hemorrhagic Shock and Resuscitation in the Rat, Cir. Shock (1989) 27 813.
Chaudry et al. Rat and Mouse Models of Hypoyolemic-Traumatic Shock Pathophysiology of Shock, Gesis, and Organ Failure 1993; pp. 171-333.
Chaudry Irshad H.
Holme Kevin R.
LandOfFree
Non-anticoagulant chemically modified heparinoids for treating h does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-anticoagulant chemically modified heparinoids for treating h, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-anticoagulant chemically modified heparinoids for treating h will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-195609